How is the Non-Alcoholic Steatohepatitis (NASH) Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the non-alcoholic steatohepatitis (nash) market?
In recent times, the market size for non-alcoholic steatohepatitis (NASH) has experienced a significant expansion. The market, which is expected to rise from $4.5 billion in 2024 to $6.13 billion in 2025, projects a compound annual growth rate (CAGR) of 36.1%. Factors attributing to this growth during the historic period include an increase in NASH occurrence, obesity outbreak, a greater understanding and detection, changes in lifestyle and diet regimes, and advancements in healthcare infrastructure.
What will be the non-alcoholic steatohepatitis (nash) market size in the future?
Get your non-alcoholic steatohepatitis (nash) market report here!
What main drivers are fueling expansion in the non-alcoholic steatohepatitis (nash) market?
The increasing prevalence of obesity is propelling the need for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by unhealthy or excessive fat accumulation and a body weight greater than what is considered appropriate for a person’s height, poses a significant health risk. The widespread occurrence of non-alcoholic fatty liver disease due to the blooming obesity epidemic potentially makes NASH the predominant cause of severe liver disease in the forthcoming years. This, in turn, fuels the necessity for NASH treatments and corresponding medications. As an illustration, in 2024, the World Health Organization (WHO), an international public health organization headquartered in the UK, reported that in 2022 around 2.5 billion adults over the age of 18 were deemed overweight, with 890 million among them being diagnosed with obesity. Hence, the surge in obesity instances will catalyze the expansion of the non-alcoholic steatohepatitis (NASH) market.
What key areas define the segmentation of the global non-alcoholic steatohepatitis (nash) market?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
Who are the dominant players expanding their reach in the non-alcoholic steatohepatitis (nash) market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
How are evolving market trends shaping non-alcoholic steatohepatitis (nash) Strategies?
The non-alcoholic steatohepatitis (NASH) market comprises significant players such as NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805
Which regions are emerging as leaders in the non-alcoholic steatohepatitis (nash) market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Non Alcoholic – Beverages Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/non-alcoholic-beverages-global-market-report
Alcoholic – Beverages Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alcoholic-beverages-global-market-report
Ethyl Alcohol And Other Basic Organic Chemical Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
